Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
- DOI
- 10.1159/000553019
- Published
- 2026-06-15
- Container
- Complementary Medicine Research
- Publisher
- S. Karger AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1159/000553019,
title = {Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial},
author = {Jia-Xin Wang and Yan-Li Xu and Cheng-Jie Ma and Guo-Dong Li and Yu-Xuan Yang and Jie Lian and Bo Li and Yi-Ying Wang and Jian-Ping Liu and Le Ngoc Hung and Ngo Thi Phuong and Le Minh Ha and Dinh Thi Lan Huong and Hui-Juan Cao},
year = {2026},
journal = {Complementary Medicine Research},
doi = {10.1159/000553019},
url = {https://doi.org/10.1159/000553019}
}RIS
TY - JOUR TI - Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial AU - Jia-Xin Wang AU - Yan-Li Xu AU - Cheng-Jie Ma AU - Guo-Dong Li AU - Yu-Xuan Yang AU - Jie Lian AU - Bo Li AU - Yi-Ying Wang AU - Jian-Ping Liu AU - Le Ngoc Hung AU - Ngo Thi Phuong AU - Le Minh Ha AU - Dinh Thi Lan Huong AU - Hui-Juan Cao PY - 2026 JO - Complementary Medicine Research DO - 10.1159/000553019 UR - https://doi.org/10.1159/000553019 ER -
APA
Wang, J., Xu, Y., Ma, C., Li, G., Yang, Y., Lian, J., Li, B., Wang, Y., Liu, J., Hung, L. N., Phuong, N. T., Ha, L. M., Huong, D. T. L., & Cao, H. (2026). Shengmai Liquid (Chinese Patent Medicine) for the Treatment of Post-COVID-19 Fatigue: A Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. Complementary Medicine Research. https://doi.org/10.1159/000553019
Source records
- crossref · retrieved 2026-11-10T07:48:27.011Z